George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
OR... look at that gap-up when there's news! : )
Only another 14 pence to go and then we can't drop any further!
Why would we be delisted. As laughable as the MC is it’s still about£10 million . You can be on aim in the hundreds of thousands. Not a cheery thought I agree. As always we are waiting on results
Roivant ends longshot lupus program after phase 2 fail
Roivant’s CEO Matt Gline always knew the lupus drug brepocitinib was a longshot: “Anybody who is not afraid of a lupus study is an idiot, you shouldn’t trust them,”
The assumption is always' they'll benefit if we benefit... but we sometimes benefit without them'.
just have to hope that, whatever the funding is and when it arrives, it's not so crushingly low that there's a good chance it bounces back to 50 before results.
We only need to 10 bag to get back to £1.50, 🫤
What a fooking shambles. I don’t think the BOD have any interest in the PI’s. They are probably busy working out if they can ring fence the IP and prevent it being sold off to settle any creditors claims. Is a Pre-pack administration a possibility if they are delisted? Tim and John won’t want their work to just disappear, plus 737 has potential value. The longer the silence the more I suspect we will get shafted.
Been here for 12 years, although I did delete my account a few years back and then just remade one recently as I felt I wanted to comment due to all the negativity.
I regretted when I was selling at 390 for not buying at 10, my average was about 70 (all post will use new money prices). So I have since done a few top ups over the past week (do expect it to fall further on funding news but I have done 12 years here I can (hopefully) do another 12).
All I remember from the 390 time is everyone thinking we are never going down again, now all I see is we are going bust.
I was selling then and I am buying now. If we go to 0 then we go to 0 but really the negative comments here just make me feel its time for buying.
I must admit I didn't think 28 was going to break downwards.
Although probably already posted by Citizen - keep up the good work.
Abstract
Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family of intracellular signalling molecules. By participating in signalling pathways downstream of type I interferons, IL-12, IL-23 and IL-10, TYK2 elicits a distinct set of immune events to JAK1, JAK2 and JAK3. TYK2 polymorphisms have been associated with susceptibility to various rheumatic diseases including systemic lupus erythematosus and dermatomyositis. In vitro and animal studies substantiate these findings, highlighting a role for TYK2 in diseases currently managed by antagonists of cytokines that signal through TYK2. Various inhibitors of TYK2 have now been studied in human disease, and one of these inhibitors, deucravacitinib, has now been approved for the treatment of psoriasis. Phase II trials of deucravacitinib have also reported positive results in the treatment of psoriatic arthritis and systemic lupus erythematosus, with a preliminary safety profile that seems to differ from that of the JAK1, JAK2 and JAK3 inhibitors. Two other inhibitors of TYK2, brepocitinib and ropsacitinib, are also in earlier stages of clinical trials. Overall, TYK2 inhibitors hold promise for the treatment of a distinct spectrum of autoimmune diseases and could potentially have a safety profile that differs from other JAK inhibitors.
Conclusions
The emergence of targeted anti-cytokine therapies has been a major breakthrough in the treatment of autoimmune and inflammatory diseases. Discoveries relating to cytokine signalling through addressable kinase targets led to the development of JAK inhibitors that showed evidence of efficacy, tolerability and safety across multiple indications. Although TYK2 is a member of the JAK family of receptor kinases, its actions are limited to a specific set of cytokines, predominantly signalling downstream of IL-12 and IL-23 and the type I interferons, and to some extent IL-10 and other cytokines, without affecting signalling downstream of classical type I cytokines or gp130 ligands such as IL-6. Recognition of the actions of TYK2, and the known efficacy of IL-12–23 blockade in psoriasis and PsA, as well as of type I interferon blockade in SLE, has spurred the development of TYK2 inhibitors in these indications. The TYK2 inhibitor deucravacitinib is now approved for the treatment of psoriasis on the basis of positive phase III trials, whereas preliminary evidence of the efficacy of deucravacitinib in phase II trials in PsA and SLE requires confirmation in the ongoing phase III trials. A potentially unique safety profile of TYK2 inhibition compared with other JAK inhibitors, on the basis of the finite list of cytokines in whose signalling it participates, was forecast and so far, upheld in clinical studies, at least with respect to laboratory evaluations. Whether the safety profile will be different from currently approved JAK inhibitors and biologic DMARDs with respect to the rarer events of MACEs, malignancy and VTE will have to await the results of much larger, longer-term studies and analyses. Two other inhibitors of TYK2, brepocitinib and ropsacitinib, are at an early stage of development and have both shown preliminary evidence of efficacy. However, consistent with their binding to the ATP binding site of JAK and also inhibiting JAK1 and/or JAK2, initial data suggest that these drugs might be more similar to the approved inhibitors of JAK1, JAK2 and/or JAK3 than deucravacitinib in terms of safety. The potential application of TYK2 inhibitors in other indications, such as in cutaneous lupus as suggested by positive findings for skin disease in the phase II SLE trial38 and dermatomyositis as suggested by evidence from genetic studies and the type I interferon signature associated with dermatomyositis75, awaits further clinical trials in these conditions, as does potential application of TYK2 inhibition for the treatment of inherited interferonopathies.
Data.
I think consolidation was the turning point here. In my experience it’s always been a complete disaster and here is no different. I’m at the point now were I just have to hold as there no point in selling out now after 14 long years! Just hope it can be turned around but I’m not holding my breath!
With respect, I would suggest that the biggest threat to Morale is the plummeting SP and the utter silence from the board.
The share price is almost down to ‘pre-consolidation’ high levels (a 50 to 1 consolidation).
Even if Robinhood wasn’t posting - morale would still be in the toilet.
The Brokers/MMs have controlled and destroyed this sp. Collusion here and at Genedrive. Anyway, all of the Fudsters are out in force ffs! Must be getting close to the new ISA allowances.
How can anyone add to see it fall? - This is potentially a big opportunity for all shareholders. For those unfortunate to buy very high I suspect there is only a limited number of shares that they could purchase at that time. They could probably get the same number of shares for peanuts here. Going bust would be the only way to lose money - your call.
I’d say it was the SP constantly being dragged down even when buys outstripped sells .The BOD have destroyed this company and it’s always the same when people say they must be in a closed period only to find out they haven’t and done jack sh@t over that period
What magic wand do you think Tim and John have...such bizarre optimism
Don't give up! Do you honestly believe that Tim & John aren't working on a plan?
The biggest threat to morale is the poster Robin Hood. A person obviously here to goad and instill fear.
If your adding to see it fall too then that's mad!
at these levels, better to wait for a climb to start, to average down as you'll still being doing so all the way up to 40p+.
Just here to wave goodbye to my money! 👋🏻 14 years I’ve been here. Such a sad state of affairs now when we were so close to a breakthrough.
Blastoid7, when the sp was skyrocketing, I'm pretty sure they issued speeding ticket RNSs to thwart the upward movement. But nothing when the sp is collapsing? Poor show. Who in their right mind will invest here when (a) the whole financing issue is still up in the air, and (b) the board are showing such utter contempt for their shareholders, many of whom have had their backs through thick and thin. If I can break even, I'm out at the earliest opportunity.
Alan. That isn't quite right is it. Tim and John deferred salary a few years ago and took shares in lieu. The BoD also bought shares and have options. They are suffering as much as anyone financially and professionally.
I appreciate that you may not wish to add but you have an opportunity here of averaging down considerably at this very low level as does anyone else.
I would sincerely hope that our BoD are locked in talks both scientifically and financially as opposed to sitting behind a desk wondering how they can appease shareholders - which lets face it - will have absolutely no impact on the sp.
Tough times for sure especially with the uncertainty, but we are where we are. I do agree though that the entire situation is one of Sareums making. Opportunity or threat? Only individuals can decide for themselves.
Hi all, I was invested in Sareum from 2020 until around the end of 2022 and I must say I'm shocked an appalled by the share price today. The Board of Directors need to hang their heads in shame considering the wind that was in their sails in 2021 and where things are now. Appointing Peel Hunt, the consolidation and the awful terms of the funding package have been crippling. I feel for all investors both long and short term - you deserve far better.
Agreed, the shareholders want and deserve an update, along with an explanation and future plan. IMMEDIATELY!
An EGM should be called for and a post-mortem of what has caused this and who should be laid open it has been a sh@t show